RNA
$13.77
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include A...
Recent News
Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal
Seven-tranche bond sale helps repay bridge loan tied to Avidity acquisition, amid $26 billion investment-grade issuance surge.
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger
Avidity Biosciences Inc. (NASDAQ:RNA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025. On February 23, Avidity Biosciences Inc. (NASDAQ:RNA) adjourned its special stockholder meeting scheduled for the same day and moved the date to February 26. Avidity Biosciences Inc. (NASDAQ:RNA) […]
European Stocks Mostly Higher in Friday Trading; French GDP Growth Slows, Inflation Rises
The European stock markets were mostly higher in Friday trading as The Stoxx Europe gained 0.2%, Ger
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA
Four months after Avidity’s $12 billion buyout, Atrium debuted with $270 million in cash and plans to pick up its predecessor’s work in cardiovascular disease.